{"id":820196,"date":"2025-03-01T17:33:03","date_gmt":"2025-03-01T22:33:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/positive-results-from-the-tezspirephase-iii-waypoint-trial-highlight-rapid-and-sustained-effect-in-chronic-rhinosinusitis-with-nasal-polyps\/"},"modified":"2025-03-01T17:33:03","modified_gmt":"2025-03-01T22:33:03","slug":"positive-results-from-the-tezspirephase-iii-waypoint-trial-highlight-rapid-and-sustained-effect-in-chronic-rhinosinusitis-with-nasal-polyps","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/positive-results-from-the-tezspirephase-iii-waypoint-trial-highlight-rapid-and-sustained-effect-in-chronic-rhinosinusitis-with-nasal-polyps\/","title":{"rendered":"Positive results from the TEZSPIREPhase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps"},"content":{"rendered":"

<\/p>\n

Positive results from the TEZSPIREPhase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps<\/b><\/p>\n

TEZSPIRE significantly reduced nasal congestion, polyp size and nearly eliminated the need for surgery in patients with chronic rhinosinusitis with nasal polyps<\/i><\/b><\/p>\n

WAYPOINT data published in New England Journal of Medicine and highlighted as late-breaking oral presentation at AAAAI\/WAO 2025<\/i><\/b><\/p>\n

WILMINGTON, Del.–(BUSINESS WIRE<\/a>)–
\nFull results from the positive Phase III WAYPOINT trial showed AstraZeneca and Amgen\u2019s TEZSPIRE\u00ae<\/sup> (tezepelumab-ekko) significantly reduced nasal polyp severity, the need for subsequent surgery, and systemic corticosteroid use in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) compared to placebo.1,2<\/sup> These data were published in the New England Journal of Medicine<\/i><\/a> and presented today as a late-breaking oral presentation at the American Academy of Allergy Asthma & Immunology (AAAAI)\/World Allergy Organization (WAO) Joint Congress in San Diego, CA.1,2<\/sup><\/p>\n

\nTreatment with TEZSPIRE significantly reduced nasal polyp severity measured by the co-primary endpoints; Nasal Polyp Score (NPS) by -2.065 (95% CI: -2.389, -1.742; p<0.0001) and nasal congestion (measured by participant-reported Nasal Congestion Score [NCS]) by -1.028 (95% CI: -1.201, -0.855; p<0.0001) at week 52 compared to placebo.1,2<\/sup> Improvements in NPS were observed as early as week four and NCS as early as week two (the first post-treatment assessment respectively) and were sustained through week 52.1<\/sup><\/p>\n

\nStatistically significant and clinically meaningful improvements were observed across all key secondary outcomes assessed in the overall trial population.1<\/sup> Importantly, TEZSPIRE significantly reduced the need for subsequent nasal polyp surgery by 98% (p<0.0001) and the need for systemic corticosteroid treatment by 88% ( p<0.0001) compared to placebo.1<\/sup><\/p>\n

\nDr Joseph Han, Vice Chair of Department of Otolaryngology – Head and Neck Surgery, Old Dominion University, US, and co-primary investigator in the trial, said: \u201cMany patients living with nasal polyps are at risk of repeat surgeries and serious systemic side effects from long-term oral corticosteroids. The WAYPOINT results are clinically meaningful and suggest that tezepelumab could greatly reduce the burden of nasal polyps for patients by nearly eliminating the need for future surgery and corticosteroid use and by significantly reducing nasal polyp size and congestion.\u201d<\/p>\n

\nSharon Barr, Executive Vice President, BioPharmaceuticals R&D said, \u201cThe WAYPOINT results demonstrate the potential for TEZSPIRE to provide a much-needed option for patients with chronic rhinosinusitis with nasal polyps. With its first-in-class mode of action, targeting TSLP at the top of the inflammatory cascade, the data add to the body of evidence that tezepelumab can transform care for patients with epithelial-driven inflammatory diseases.\u201d<\/p>\n

Table M1: Summary of co-primary and key secondary efficacy endpoints1,2<\/sup><\/b><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

Endpoint<\/b><\/p>\n<\/td>\n

\n

Tezepelumab (n=203)<\/b><\/p>\n<\/td>\n

\n

Placebo (n=205)<\/b><\/p>\n<\/td>\n

\n

Difference vs. Placebo<\/b><\/p>\n

(95% CI)<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

Co-primary endpoints<\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\nTotal nasal polyp score (range 0-8)*<\/p>\n<\/td>\n

\n

\n-2.458 (0.114)<\/p>\n<\/td>\n

\n

\n-0.392 (0.118)<\/p>\n<\/td>\n

\n

\n-2.065 (-2.389, -1.742)<\/p>\n

\np<0.0001**<\/p>\n<\/td>\n<\/tr>\n

\n

\nNasal congestion score (range 0-3)*<\/p>\n<\/td>\n

\n

\n-1.743 (0.062)<\/p>\n<\/td>\n

\n

\n-0.715 (0.064)<\/p>\n<\/td>\n

\n

\n-1.028 (-1.201, -0.855)<\/p>\n

\np<0.0001**<\/p>\n<\/td>\n<\/tr>\n

\n

Key secondary endpoints<\/b><\/p>\n

Assessed in the overall trial population<\/i><\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\nTime to first nasal polyp surgery decision<\/p>\n

\n(% patients)***<\/p>\n<\/td>\n

\n

\n0.5 (0.0, 2.5)<\/p>\n<\/td>\n

\n

\n22.1 (16.4, 28.2)<\/p>\n<\/td>\n

\n

\n0.02 (0.00, 0.09)<\/p>\n

\np<0.0001**<\/p>\n<\/td>\n<\/tr>\n

\n

\nTime to first systemic glucocorticoid use<\/p>\n

\n(% patients)***<\/p>\n<\/td>\n

\n

\n5.2 (1.1, 14.7)<\/p>\n<\/td>\n

\n

\n18.3 (13.3, 24.1)<\/p>\n<\/td>\n

\n

\n0.12 (0.04, 0.27)<\/p>\n

\np<0.0001**<\/p>\n<\/td>\n<\/tr>\n

\n

\nTime to nasal polyp surgery decision and\/or systemic glucocorticoid use<\/p>\n

\n(% patients)***<\/p>\n<\/td>\n

\n

\n5.7 (1.3, 15.0)<\/p>\n<\/td>\n

\n

\n30.6 (24.2, 37.1)<\/p>\n<\/td>\n

\n

\n0.08 (0.03, 0.17)<\/p>\n

\np<0.0001**<\/p>\n<\/td>\n<\/tr>\n

\n

\nLoss of smell score<\/p>\n

\n(range 0-3)*<\/p>\n<\/td>\n

\n

\n-1.26 (0.06)<\/p>\n<\/td>\n

\n

\n-0.26 (0.06)<\/p>\n<\/td>\n

\n

\n-1.00 (-1.18, -0.83)<\/p>\n

\np<0.0001**<\/p>\n<\/td>\n<\/tr>\n

\n

\nSino-Nasal Outcome Test-22 (SNOT-22) total score<\/p>\n

\n(range 0-110)*<\/p>\n<\/td>\n

\n

\n-45.02 (1.81)<\/p>\n<\/td>\n

\n

\n-17.76 (1.84)<\/p>\n<\/td>\n

\n

\n-27.26 (-32.32, -22.21)<\/p>\n

\np<0.0001**<\/p>\n<\/td>\n<\/tr>\n

\n

\nSinus Computed Tomography Lund\u2013Mackay (CT-LMK) score<\/p>\n

\n(range 0-24)*<\/p>\n<\/td>\n

\n

\n-6.27 (0.24)<\/p>\n<\/td>\n

\n

\n-0.55 (0.24)<\/p>\n<\/td>\n

\n

\n-5.72 (-6.39, -5.06)<\/p>\n

\np<0.0001**<\/p>\n<\/td>\n<\/tr>\n

\n

\nTotal Symptom Score (TSS)<\/p>\n

\n(range 0-24)*<\/p>\n<\/td>\n

\n

\n-10.39 (0.40)<\/p>\n<\/td>\n

\n

\n-3.50 (0.41)<\/p>\n<\/td>\n

\n

\n-6.89 (-8.02, -5.76)<\/p>\n

\np<0.0001**<\/p>\n<\/td>\n<\/tr>\n

\n

Key secondary endpoint<\/b><\/p>\n

Assessed in a subset of patients with co-morbid asthma or nonsteroidal anti-inflammatory drug exacerbated respiratory disease<\/i><\/b><\/p>\n<\/td>\n<\/tr>\n

\n

\nPre-bronchodilator forced expiratory volume in 1 second (FEV1 in liters)*<\/p>\n<\/td>\n

\n

\n0.02 (0.04)<\/p>\n<\/td>\n

\n

\n0.03 (0.04)<\/p>\n<\/td>\n

\n

\n-0.01 (-0.12, 0.11)<\/p>\n

\np=0.9362<\/p>\n<\/td>\n<\/tr>\n

\n

\n*LS mean change (SE) from baseline at Week 52<\/p>\n<\/td>\n<\/tr>\n

\n

\n**Denotes statistically significant at 0.01 level after adjustment for multiplicity. Unadjusted P-values are presented<\/p>\n<\/td>\n<\/tr>\n

\n

\n*** % patients from Kaplan Meier estimate (95% confidence interval) is provided for each treatment group, hazard ratio (95% confidence interval) is presented for the difference vs placebo.<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nTEZSPIRE was generally well tolerated in patients with CRSwNP and had a safety profile consistent with its approved severe asthma indication.1,2<\/sup> The most frequently reported adverse events for TEZSPIREin the WAYPOINT trial were COVID-19, nasopharyngitis and upper respiratory tract infection.1<\/sup> There were no clinically meaningful differences in safety results between the TEZSPIREand placebo group.1<\/sup><\/p>\n

\nTEZSPIREis currently approved for the treatment of severe asthma in the US, EU, Japan, and over 60 countries across the globe.3-5<\/sup> It is approved as a single-use pre-filled syringe and auto-injector for self-administration in the US and EU.3,4<\/sup> Regulatory filings for tezepelumab in CRSwNP are currently under review by regulatory authorities in multiple regions.<\/p>\n

INDICATION AND LIMITATION OF USE \/ ISI<\/b><\/p>\n

TEZSPIRE\u00ae<\/sup> (tezepelumab-ekko)<\/b><\/p>\n

INDICATION<\/b><\/p>\n

\nTEZSPIRE is indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.<\/p>\n

\nTEZSPIRE is not indicated for the relief of acute bronchospasm or status asthmaticus.<\/p>\n

CONTRAINDICATIONS<\/b><\/p>\n

\nKnown hypersensitivity to tezepelumab-ekko or excipients.<\/p>\n

WARNINGS AND PRECAUTIONS<\/b><\/p>\n

Hypersensitivity Reactions<\/b><\/p>\n

\nHypersensitivity reactions were observed in the clinical trials (eg, rash and allergic conjunctivitis) following the administration of TEZSPIRE. Postmarketing cases of anaphylaxis have been reported. These reactions can occur within hours of administration, but in some instances have a delayed onset (ie, days). In the event of a hypersensitivity reaction, consider the benefits and risks for the individual patient to determine whether to continue or discontinue treatment with TEZSPIRE.<\/p>\n

Acute Asthma Symptoms or Deteriorating Disease<\/b><\/p>\n

\nTEZSPIRE should not be used to treat acute asthma symptoms, acute exacerbations, acute bronchospasm, or status asthmaticus.<\/p>\n

Abrupt Reduction of Corticosteroid Dosage<\/b><\/p>\n

\nDo not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with TEZSPIRE. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a physician. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and\/or unmask conditions previously suppressed by systemic corticosteroid therapy.<\/p>\n

Parasitic (Helminth) Infection<\/b><\/p>\n

\nIt is unknown if TEZSPIRE will influence a patient\u2019s response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with TEZSPIRE. If patients become infected while receiving TEZSPIRE and do not respond to anti-helminth treatment, discontinue TEZSPIRE until infection resolves.<\/p>\n

Live Attenuated Vaccines<\/b><\/p>\n

\nThe concomitant use of TEZSPIRE and live attenuated vaccines has not been evaluated. The use of live attenuated vaccines should be avoided in patients receiving TEZSPIRE.<\/p>\n

ADVERSE REACTIONS<\/b><\/p>\n

\nThe most common adverse reactions (incidence \u22653%) are pharyngitis, arthralgia, and back pain.<\/p>\n

USE IN SPECIFIC POPULATIONS<\/b><\/p>\n

\nThere are no available data on TEZSPIRE use in pregnant women to evaluate for any drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Placental transfer of monoclonal antibodies such as tezepelumab-ekko is greater during the third trimester of pregnancy; therefore, potential effects on a fetus are likely to be greater during the third trimester of pregnancy.<\/p>\n

Please see full <\/b>Prescribing Information<\/b><\/a>, including <\/b>Patient Information<\/b><\/a> and <\/b>Instructions for Use<\/b><\/a>.<\/b><\/p>\n

You may <\/i>report side effects related to AstraZeneca products.<\/i><\/a><\/p>\n

Notes<\/span><\/b><\/p>\n

Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)<\/b><\/p>\n

\nCRSwNP is a complex inflammatory disorder, characterized by persistent inflammation of the nasal mucosa accompanied by benign growths, called nasal polyps.6,7<\/sup> Nasal polyps and the accompanying inflammation can block nasal passages and lead to breathing problems, difficulty in sense of smell, nasal discharge, facial pain, sleep disturbance and other adverse effects on quality of life.8-10 <\/sup>Current treatments for CRSwNP include intranasal and\/or systemic corticosteroids, surgery and biologics.7,10-16<\/sup><\/p>\n

Phase III WAYPOINT trial<\/b><\/p>\n

\nWAYPOINT was a double-blind, multi-centre, randomized, placebo-controlled, parallel group trial designed to evaluate the efficacy and safety of tezepelumab in adults with severe CRSwNP.1,2,17 <\/sup>Participants received tezepelumab or placebo, administered via subcutaneous injection.1,2,17<\/sup> The trial also included a post-treatment follow-up period of 12-24 weeks for participants who completed the 52-week treatment period.1,17<\/sup><\/p>\n

TEZSPIRE<\/b><\/p>\n

\nTEZSPIRE\u00ae<\/sup> (tezepelumab) is being developed by AstraZeneca in collaboration with Amgen as a first-in-class human monoclonal antibody that inhibits the action of thymic stromal lymphopoietin (TSLP), a key epithelial cytokine that sits at the top of multiple inflammatory cascades and is critical in the initiation and persistence of allergic, eosinophilic, and other types of epithelial-driven inflammation associated with severe asthma and other inflammatory diseases.18,19<\/sup><\/p>\n

\nTSLP is released in response to multiple epithelial triggers and insults (including allergens, viruses, bacteria, smoke, air pollution and other airborne particles) associated with asthma, CRSwNP, chronic obstructive pulmonary disease (COPD), eosinophilic esophagitis (EoE) and other diseases.19,20<\/sup> Expression of TSLP is increased in these patients and has been correlated with disease severity.10,18<\/sup> Blocking TSLP can prevent the release of pro-inflammatory cytokines by immune cells, resulting in the prevention of exacerbations and improved disease control.18,19,21<\/sup> Tezepelumabacts at the top of the inflammatory cascade and research indicates that targeting TSLP released by the airway and gastrointestinal epithelium may be a potential approach to treating other diseases in the future.18,22,23<\/sup><\/p>\n

\nTEZSPIRE is approved in the US, the EU and over 60 countries for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.3-5<\/sup><\/p>\n

\nBeyond CRSwNP, tezepelumabis also in development for other potential indications including COPD and EoE.24,25<\/sup> In October 2021, tezepelumab was granted Orphan Drug Designation<\/a> by the US Food and Drug Administration (FDA) for the treatment of EoE. In July 2024, the US FDA granted a Breakthrough Therapy Designation for tezepelumabfor the add-on maintenance treatment of patients with moderate to very severe COPD characterized by an eosinophilic phenotype.<\/p>\n

Amgen collaboration<\/b><\/p>\n

\nIn 2020, Amgen and AstraZeneca updated a 2012 collaboration agreement<\/a> for TEZSPIRE. Both companies will continue to share costs and profits equally after payment by AstraZeneca of a mid-single-digit inventor royalty to Amgen. AstraZeneca continues to lead development, and Amgen continues to lead manufacturing. All aspects of the collaboration are under the oversight of joint governing bodies. Under the amended agreement, Amgen and AstraZeneca will jointly commercialize TEZSPIRE in North America. Amgen will record product sales in the US, with AZ recording its share of US profits as Collaboration Revenue. Outside of the US, AstraZeneca will record product sales, with Amgen recording profit share as Other\/Collaboration revenue.<\/p>\n

AstraZeneca in Respiratory & Immunology<\/b><\/p>\n

\nRespiratory & Immunology, part of AstraZeneca BioPharmaceuticals is a key disease area and growth driver to the Company.<\/p>\n

\nAstraZeneca is an established leader in respiratory care with a 50-year heritage and a growing portfolio of medicines in immune-mediated diseases. The Company is committed to addressing the vast unmet needs of these chronic, often debilitating, diseases with a pipeline and portfolio of inhaled medicines, biologics and new modalities aimed at previously unreachable biologic targets. Our ambition is to deliver life-changing medicines that help eliminate COPD as a leading cause of death, eliminate asthma attacks and achieve clinical remission in immune-mediated diseases.<\/p>\n

AstraZeneca<\/b><\/p>\n

\nAstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 125 countries, and its innovative medicines are used by millions of patients worldwide. Please visit www.astrazeneca-us.com<\/a> and follow the Company on social media @AstraZeneca<\/a><\/p>\n

References<\/b><\/p>\n

    \n
  1. \nLipworth, BJ, Han JK, et al<\/i>. Tezepelumab in adults with severe, uncontrolled CRSwNP. N Engl J Med<\/i>. 2025.<\/p>\n<\/li>\n
  2. \nLipworth, BJ, Han JK, et al<\/i>. Efficacy and safety of tezepelumab in adults with severe chronic rhinosinusitis with nasal polyps: results from the Phase 3 WAYPOINT Study. [Late breaking oral presentation]. Presented at the American Academy of Allergy, Asthma & Immunology \/World Allergy Organization Joint Congress 2025 (28 February \u2013 03 March).<\/p>\n<\/li>\n
  3. \nTEZSPIRE (tezepelumab) US prescribing information. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761224s003lbl.pdf<\/a>. [Last accessed: February 2025].<\/p>\n<\/li>\n
  4. \nTEZSPIRE(tezepelumab) Summary of Product Characteristics. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tezspire-epar-product-information_en.pdf<\/a>. [Last accessed: February 2025].<\/p>\n<\/li>\n
  5. \nAstraZeneca plc. TEZSPIREapproved in Japan for the treatment of severe asthma. Available at: https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2022\/tezspire-approved-in-japan-for-severe-asthma.html<\/a>. [Last accessed: February 2025].<\/p>\n<\/li>\n
  6. \nBachert C, et al<\/i>. Phenotypes and Emerging Endotypes of Chronic Rhinosinusitis. J Allergy Clin Immunol Pract.<\/i> 2016; 4 (4): 621-628.<\/p>\n<\/li>\n
  7. \nDel Toro E, Portela J. Nasal Polyps. [Updated 2023 Jul 31]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK560746\/<\/a> [Last accessed: February 2025].<\/p>\n<\/li>\n
  8. \nStevens WW, et al<\/i>. Chronic Rhinosinusitis with Nasal Polyps. J Allergy Clin Immunol Pract<\/i>. 2016; 4 (4): 565-572.<\/p>\n<\/li>\n
  9. \nAbdalla S, et al<\/i>. Prevalence of sinonasal outcome test (SNOT-22) symptoms in patients undergoing surgery for chronic rhinosinusitis in the England and Wales National prospective audit. Clin Otolaryngol<\/i>. 2012; 37 (4): 276-282.<\/p>\n<\/li>\n
  10. \nChen S et al<\/i>. Systematic literature review of the epidemiology and clinical burden of chronic rhinosinusitis with nasal polyposis. Curr Med Res Opin. 2020;36(11):1897-1911.<\/p>\n<\/li>\n
  11. \nXolair (omalizumab) Summary of Product Characteristics; Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xolair-epar-product-information_en.pdf<\/a>. [Last accessed: February 2025].<\/p>\n<\/li>\n
  12. \nXolair (omalizumab) US prescribing information; Available at: https:\/\/www.gene.com\/download\/pdf\/xolair_prescribing.pdf<\/a> [Last accessed: February 2025].<\/p>\n<\/li>\n
  13. \nNucala (mepolizumab) Summary of Product Characteristics. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/nucala-epar-product-information_en.pdf<\/a>. [Last accessed: February 2025].<\/p>\n<\/li>\n
  14. \nNucala (mepolizumab) US prescribing information; Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761122s006,125526s018lbl.pdf<\/a>. [Last accessed: February 2025].<\/p>\n<\/li>\n
  15. \nDupixent (dupilumab) Summary of Product Characteristics. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/dupixent-epar-product-information_en.pdf<\/a>. [Last accessed: February 2025].<\/p>\n<\/li>\n
  16. \nDupixent (dupilumab) US prescribing information; Available at: https:\/\/www.regeneron.com\/downloads\/dupixent_fpi.pdf<\/a>. [Last accessed: February 2025].<\/p>\n<\/li>\n
  17. \nClinicaltrials.gov. Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis (WAYPOINT). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04851964<\/a>. [Last accessed: February 2025].<\/p>\n<\/li>\n
  18. \nCorren J, et al<\/i>. Tezepelumab in adults with uncontrolled asthma. N Engl J Med<\/i>. 2017;377:936-946.<\/p>\n<\/li>\n
  19. \nVarricchi G, et al<\/i>. Thymic Stromal Lymphopoietin Isoforms, Inflammatory Disorders, and Cancer. Front Immunol<\/i>. 2018;9:1595.<\/p>\n<\/li>\n
  20. \nZhang M, et al<\/i>. Hypoxia induces the production of epithelial-derived cytokines in eosinophilic chronic rhinosinusitis with nasal polyps. Int Immunopharmacol.<\/i> 2023;121:110559.<\/p>\n<\/li>\n
  21. \nLi Y, et al<\/i>. Elevated Expression of IL-33 and TSLP in the Airways of Human Asthmatics In Vivo: A Potential Biomarker of Severe Refractory Disease. J Immunol<\/i>. 2018;200: 2253\u20132262.<\/p>\n<\/li>\n
  22. \nMenzies-Gow A, et al<\/i>. Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma. N Engl J Med<\/i>. 2021;384:1800-1809.<\/p>\n<\/li>\n
  23. \nLaidlaw TM et al<\/i>. Tezepelumab Efficacy in Patients with Severe, Uncontrolled Asthma with Comorbid Nasal Polyps in NAVIGATOR. J Asthma Allergy<\/i>. 2023 Sep 4:16:915-932.<\/p>\n<\/li>\n
  24. \nClinicaltrials.gov. Tezepelumab COPD Exacerbation Study (COURSE) [Online]. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04039113<\/a>. [Last accessed: February 2025].<\/p>\n<\/li>\n
  25. \nClinicaltrials.gov. Efficacy and Safety of Tezepelumab in Patients with Eosinophilic Esophagitis (CROSSING). Available at: https:\/\/clinicaltrials.gov\/study\/NCT05583227?rank=1<\/a>. [Last accessed: February 2025].<\/p>\n<\/li>\n<\/ol>\n

    \"\"<\/p>\n

    View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20250301104112\/en\/<\/a><\/span><\/p>\n

    Media Inquiries
    \n<\/b>
    Fiona Cookson +1 212 814 3923
    \n
    Jillian Gonzales +1 302 885 2677
    \n
    US Media Mailbox:     usmediateam@astrazeneca.com<\/a><\/p>\n

    KEYWORDS:<\/b> Delaware United States North America<\/p>\n

    INDUSTRY KEYWORDS:<\/b> Health Clinical Trials Research Pharmaceutical Science Biotechnology<\/p>\n

    MEDIA:<\/b><\/p>\n\n\n\n\n
    Logo<\/b><\/font><\/td>\n<\/tr>\n
    \"Logo\"<\/td>\n<\/tr>\n
    <\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

    Positive results from the TEZSPIREPhase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps TEZSPIRE significantly reduced nasal congestion, polyp size and nearly eliminated the need for surgery in patients with chronic rhinosinusitis with nasal polyps WAYPOINT data published in New England Journal of Medicine and highlighted as late-breaking oral presentation at AAAAI\/WAO 2025 WILMINGTON, Del.–(BUSINESS WIRE)– Full results from the positive Phase III WAYPOINT trial showed AstraZeneca and Amgen\u2019s TEZSPIRE\u00ae (tezepelumab-ekko) significantly reduced nasal polyp severity, the need for subsequent surgery, and systemic corticosteroid use in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) compared to placebo.1,2 These data were published in the New England Journal of Medicine and presented today as a late-breaking … <\/p>\n

    Continue reading “Positive results from the TEZSPIREPhase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-820196","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nPositive results from the TEZSPIREPhase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/positive-results-from-the-tezspirephase-iii-waypoint-trial-highlight-rapid-and-sustained-effect-in-chronic-rhinosinusitis-with-nasal-polyps\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Positive results from the TEZSPIREPhase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Positive results from the TEZSPIREPhase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps TEZSPIRE significantly reduced nasal congestion, polyp size and nearly eliminated the need for surgery in patients with chronic rhinosinusitis with nasal polyps WAYPOINT data published in New England Journal of Medicine and highlighted as late-breaking oral presentation at AAAAI\/WAO 2025 WILMINGTON, Del.–(BUSINESS WIRE)– Full results from the positive Phase III WAYPOINT trial showed AstraZeneca and Amgen\u2019s TEZSPIRE\u00ae (tezepelumab-ekko) significantly reduced nasal polyp severity, the need for subsequent surgery, and systemic corticosteroid use in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) compared to placebo.1,2 These data were published in the New England Journal of Medicine and presented today as a late-breaking … Continue reading "Positive results from the TEZSPIREPhase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/positive-results-from-the-tezspirephase-iii-waypoint-trial-highlight-rapid-and-sustained-effect-in-chronic-rhinosinusitis-with-nasal-polyps\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-01T22:33:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250301104112r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"12 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/positive-results-from-the-tezspirephase-iii-waypoint-trial-highlight-rapid-and-sustained-effect-in-chronic-rhinosinusitis-with-nasal-polyps\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/positive-results-from-the-tezspirephase-iii-waypoint-trial-highlight-rapid-and-sustained-effect-in-chronic-rhinosinusitis-with-nasal-polyps\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Positive results from the TEZSPIREPhase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps\",\"datePublished\":\"2025-03-01T22:33:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/positive-results-from-the-tezspirephase-iii-waypoint-trial-highlight-rapid-and-sustained-effect-in-chronic-rhinosinusitis-with-nasal-polyps\\\/\"},\"wordCount\":2426,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/positive-results-from-the-tezspirephase-iii-waypoint-trial-highlight-rapid-and-sustained-effect-in-chronic-rhinosinusitis-with-nasal-polyps\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250301104112r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/positive-results-from-the-tezspirephase-iii-waypoint-trial-highlight-rapid-and-sustained-effect-in-chronic-rhinosinusitis-with-nasal-polyps\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/positive-results-from-the-tezspirephase-iii-waypoint-trial-highlight-rapid-and-sustained-effect-in-chronic-rhinosinusitis-with-nasal-polyps\\\/\",\"name\":\"Positive results from the TEZSPIREPhase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/positive-results-from-the-tezspirephase-iii-waypoint-trial-highlight-rapid-and-sustained-effect-in-chronic-rhinosinusitis-with-nasal-polyps\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/positive-results-from-the-tezspirephase-iii-waypoint-trial-highlight-rapid-and-sustained-effect-in-chronic-rhinosinusitis-with-nasal-polyps\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250301104112r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2025-03-01T22:33:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/positive-results-from-the-tezspirephase-iii-waypoint-trial-highlight-rapid-and-sustained-effect-in-chronic-rhinosinusitis-with-nasal-polyps\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/positive-results-from-the-tezspirephase-iii-waypoint-trial-highlight-rapid-and-sustained-effect-in-chronic-rhinosinusitis-with-nasal-polyps\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/positive-results-from-the-tezspirephase-iii-waypoint-trial-highlight-rapid-and-sustained-effect-in-chronic-rhinosinusitis-with-nasal-polyps\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250301104112r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250301104112r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/positive-results-from-the-tezspirephase-iii-waypoint-trial-highlight-rapid-and-sustained-effect-in-chronic-rhinosinusitis-with-nasal-polyps\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Positive results from the TEZSPIREPhase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Positive results from the TEZSPIREPhase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/positive-results-from-the-tezspirephase-iii-waypoint-trial-highlight-rapid-and-sustained-effect-in-chronic-rhinosinusitis-with-nasal-polyps\/","og_locale":"en_US","og_type":"article","og_title":"Positive results from the TEZSPIREPhase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps - Market Newsdesk","og_description":"Positive results from the TEZSPIREPhase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps TEZSPIRE significantly reduced nasal congestion, polyp size and nearly eliminated the need for surgery in patients with chronic rhinosinusitis with nasal polyps WAYPOINT data published in New England Journal of Medicine and highlighted as late-breaking oral presentation at AAAAI\/WAO 2025 WILMINGTON, Del.–(BUSINESS WIRE)– Full results from the positive Phase III WAYPOINT trial showed AstraZeneca and Amgen\u2019s TEZSPIRE\u00ae (tezepelumab-ekko) significantly reduced nasal polyp severity, the need for subsequent surgery, and systemic corticosteroid use in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) compared to placebo.1,2 These data were published in the New England Journal of Medicine and presented today as a late-breaking … Continue reading \"Positive results from the TEZSPIREPhase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/positive-results-from-the-tezspirephase-iii-waypoint-trial-highlight-rapid-and-sustained-effect-in-chronic-rhinosinusitis-with-nasal-polyps\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-01T22:33:03+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250301104112r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"12 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/positive-results-from-the-tezspirephase-iii-waypoint-trial-highlight-rapid-and-sustained-effect-in-chronic-rhinosinusitis-with-nasal-polyps\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/positive-results-from-the-tezspirephase-iii-waypoint-trial-highlight-rapid-and-sustained-effect-in-chronic-rhinosinusitis-with-nasal-polyps\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Positive results from the TEZSPIREPhase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps","datePublished":"2025-03-01T22:33:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/positive-results-from-the-tezspirephase-iii-waypoint-trial-highlight-rapid-and-sustained-effect-in-chronic-rhinosinusitis-with-nasal-polyps\/"},"wordCount":2426,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/positive-results-from-the-tezspirephase-iii-waypoint-trial-highlight-rapid-and-sustained-effect-in-chronic-rhinosinusitis-with-nasal-polyps\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250301104112r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/positive-results-from-the-tezspirephase-iii-waypoint-trial-highlight-rapid-and-sustained-effect-in-chronic-rhinosinusitis-with-nasal-polyps\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/positive-results-from-the-tezspirephase-iii-waypoint-trial-highlight-rapid-and-sustained-effect-in-chronic-rhinosinusitis-with-nasal-polyps\/","name":"Positive results from the TEZSPIREPhase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/positive-results-from-the-tezspirephase-iii-waypoint-trial-highlight-rapid-and-sustained-effect-in-chronic-rhinosinusitis-with-nasal-polyps\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/positive-results-from-the-tezspirephase-iii-waypoint-trial-highlight-rapid-and-sustained-effect-in-chronic-rhinosinusitis-with-nasal-polyps\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250301104112r1&sid=flmnd&distro=nx&lang=en","datePublished":"2025-03-01T22:33:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/positive-results-from-the-tezspirephase-iii-waypoint-trial-highlight-rapid-and-sustained-effect-in-chronic-rhinosinusitis-with-nasal-polyps\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/positive-results-from-the-tezspirephase-iii-waypoint-trial-highlight-rapid-and-sustained-effect-in-chronic-rhinosinusitis-with-nasal-polyps\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/positive-results-from-the-tezspirephase-iii-waypoint-trial-highlight-rapid-and-sustained-effect-in-chronic-rhinosinusitis-with-nasal-polyps\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250301104112r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250301104112r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/positive-results-from-the-tezspirephase-iii-waypoint-trial-highlight-rapid-and-sustained-effect-in-chronic-rhinosinusitis-with-nasal-polyps\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Positive results from the TEZSPIREPhase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/820196","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=820196"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/820196\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=820196"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=820196"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=820196"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}